Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial, Lancet, vol.376, pp.1147-1154, 2010. ,
Abiraterone and increased survival in metastatic prostate cancer, N. Engl. J. Med, vol.364, 1995. ,
Enzalutamide in metastatic prostate cancer before chemotherapy, N. Engl. J. Med, vol.371, pp.424-433, 2014. ,
URL : https://hal.archives-ouvertes.fr/hal-02169779
Sipuleucel-T immunotherapy for castration-resistant prostate cancer, N. Engl. J. Med, vol.363, pp.411-422, 2010. ,
Alpha emitter radium-223 and survival in metastatic prostate cancer, N. Engl. J. Med, vol.369, pp.213-223, 2013. ,
Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer, N. Engl. J. Med, vol.351, pp.1513-1520, 2004. ,
Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer, Nat. Med, vol.22, pp.298-305, 2016. ,
Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets, Cancer Discov, vol.1, pp.487-495, 2011. ,
Proposed morphologic classification of prostate cancer with neuroendocrine differentiation, Am. J. Surg. Pathol, vol.38, pp.756-767, 2014. ,
Organoid cultures derived from patients with advanced prostate cancer, Cell, vol.159, pp.176-187, 2014. ,
Single-cell analyses of prostate cancer liquid biopsies acquired by apheresis, Clin. Cancer Res, vol.24, pp.5635-5644, 2018. ,
Patient derived organoids to model rare prostate cancer phenotypes, Nat. Commun, vol.9, p.2404, 2018. ,
Application of prostate cancer models for preclinical study: advantages and limitations of cell lines, patient-derived xenografts, and three-dimensional culture of patient-derived cells, Cells, vol.8, p.74, 2019. ,
A neuroendocrine/small cell prostate carcinoma xenograft-LuCaP 49, Am. J. Pathol, vol.161, pp.705-715, 2002. ,
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer, Clin. Cancer Res, vol.14, pp.6302-6309, 2008. ,
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience, Ann. Oncol, vol.20, pp.27-33, 2009. ,
Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: a report from the PETRUS prospective study, Oncotarget, vol.7, pp.55069-55082, 2016. ,
Characterization of ERG, AR and PTEN gene status in circulating tumor cells from patients with castration-resistant prostate cancer, Cancer Res, vol.69, pp.2912-2918, 2009. ,
Diagnostic leukapheresis enables reliable detection of circulating tumor cells of nonmetastatic cancer patients, Proc. Natl Acad. Sci. USA, vol.110, pp.16580-16585, 2013. ,
Toward a real liquid biopsy in metastatic breast and prostate cancer: diagnostic leukapheresis increases CTC yields in a European prospective multicenter study (CTCTrap), Int. J. Cancer, vol.143, pp.2584-2591, 2018. ,
Diagnostic leukapheresis for CTC analysis in breast cancer patients: CTC frequency, clinical experiences and recommendations for standardized reporting, Cytometry A, vol.93, pp.1213-1219, 2018. ,
Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay, Nat. Biotechnol, vol.31, pp.539-544, 2013. ,
Tumorigenicity and genetic profiling of circulating tumor cells in small-cell lung cancer, Nat. Med, vol.20, pp.897-903, 2014. ,
Application of sequencing, liquid biopsies, and patientderived xenografts for personalized medicine in melanoma, Cancer Discov, vol.6, pp.286-299, 2016. ,
Tumourigenic non-small-cell lung cancer mesenchymal circulating tumour cells: a clinical case study, Ann. Oncol, vol.27, pp.1155-1160, 2016. ,
Establishment and characterization of a cell line from human circulating colon cancer cells, Cancer Res, vol.75, pp.892-901, 2015. ,
URL : https://hal.archives-ouvertes.fr/hal-01990012
Ex vivo culture of circulating breast tumor cells for individualized testing of drug susceptibility, Science, vol.345, pp.216-220, 2014. ,
Clinical and genomic characterization of treatmentemergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study, J. Clin. Oncol, vol.36, pp.2492-2503, 2018. ,
Transdifferentiation as a mechanism of treatment resistance in a mouse model of castration-resistant prostate cancer, Cancer Discov, vol.7, pp.736-749, 2017. ,
The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data, Cancer Discov, vol.2, pp.401-404, 2012. ,
Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal, Sci. Signal, vol.6, p.1, 2013. ,
Potentiation of antitumour activity of docetaxel by combination with trastuzumab in a human prostate cancer xenograft model and underlying mechanisms, Br. J. Cancer, vol.96, pp.269-276, 2007. ,
Establishment and characterization of a human prostatic carcinoma cell line (PC-3), Invest. Urol, vol.17, pp.16-23, 1979. ,
PC3 is a cell line characteristic of prostatic small cell carcinoma, Prostate, vol.71, pp.1668-1679, 2011. ,
Multifocal primary prostate cancer exhibits high degree of genomic heterogeneity, Eur. Urol, vol.75, pp.498-505, 2018. ,
Whole-exome sequencing of circulating tumor cells provides a window into metastatic prostate cancer, Nat. Biotechnol, vol.32, pp.479-484, 2014. ,
Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance, Science, vol.355, pp.78-83, 2017. ,
Compound genomic alterations of TP53, PTEN, and RB1 tumor suppressors in localized and metastatic prostate cancer, Eur. Urol, vol.77, pp.89-97, 2018. ,
SOX2 promotes lineage plasticity and antiandrogen resistance in TP53-and RB1-deficient prostate cancer, Science, vol.355, pp.84-88, 2017. ,
Proteogenomic characterization of patient-derived xenografts highlights the role of REST in neuroendocrine differentiation of castration-resistant prostate cancer, Clin. Cancer Res, vol.25, pp.595-608, 2019. ,
Elevated circulating tissue inhibitor of metalloproteinase 1 (TIMP-1) levels are associated with neuroendocrine differentiation in castration resistant prostate cancer, Prostate, vol.75, pp.616-627, 2015. ,
Neuroendocrine cells in human prostate over-express the anti-apoptosis protein survivin, Prostate, vol.48, pp.7-15, 2001. ,
Genome doubling shapes the evolution and prognosis of advanced cancers, Nat. Genet, vol.50, pp.1189-1195, 2018. ,
Molecular profiling of single circulating tumor cells with diagnostic intention, EMBO Mol. Med, vol.6, pp.1371-1386, 2014. ,
Solution hybrid selection with ultra-long oligonucleotides for massively parallel targeted sequencing, Nat. Biotechnol, vol.27, pp.182-189, 2009. ,
Cutadapt removes adapter sequences from high-throughput sequencing reads, EMBnet J, vol.17, p.10, 2011. ,
Next-generation sequencing analysis and algorithms for PDX and CDX models, Mol. Cancer Res, vol.15, pp.1012-1016, 2017. ,
Fast and accurate short read alignment with Burrows-Wheeler transform, Bioinformatics, vol.25, pp.1754-1760, 2009. ,
Sambamba: fast processing of NGS alignment formats, Bioinformatics, vol.31, pp.2032-2034, 2015. ,
A framework for variation discovery and genotyping using next-generation DNA sequencing data, Nat. Genet, vol.43, pp.491-498, 2011. ,
From FastQ data to high confidence variant calls: the Genome Analysis Toolkit best practices pipeline, Curr. Protoc. Bioinformatics, vol.43, p.33, 2013. ,
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples, Nat. Biotechnol, vol.31, pp.213-219, 2013. ,
The Ensembl Variant Effect Predictor, Genome Biol, vol.17, p.122, 2016. ,
Cancer Genome Interpreter annotates the biological and clinical relevance of tumor alterations, Genome Med, vol.10, p.25, 2018. ,
A faster circular binary segmentation algorithm for the analysis of array CGH data, Bioinformatics, vol.23, pp.657-663, 2007. ,
Genome Alteration Print (GAP): a tool to visualize and mine complex cancer genomic profiles obtained by SNP arrays, Genome Biol, vol.10, p.128, 2009. ,
URL : https://hal.archives-ouvertes.fr/inserm-00663915
, phylogenetic analysis in R, vol.27, pp.592-593, 2011.
The Parsimony Ratchet, a new method for rapid parsimony analysis, Cladistics, vol.15, pp.407-414, 1999. ,
STAR: ultrafast universal RNA-seq aligner, Bioinformatics, vol.29, pp.15-21, 2013. ,
Differential expression analysis for sequence count data, Genome Biol, vol.11, p.106, 2010. ,
RSeQC: quality control of RNA-seq experiments, Bioinformatics, vol.28, pp.2184-2185, 2012. ,
A scaling normalization method for differential expression analysis of RNA-seq data, Genome Biol, vol.11, p.25, 2010. ,
limma powers differential expression analyses for RNAsequencing and microarray studies, Nucleic Acids Res, vol.43, p.47, 2015. ,
The mutational landscape of lethal castration-resistant prostate cancer, Nature, vol.487, pp.239-243, 2012. ,
Punctuated evolution of prostate cancer genomes, Cell, vol.153, pp.666-677, 2013. ,
Integrative clinical genomics of advanced prostate cancer, Cell, vol.161, pp.1215-1228, 2015. ,
Substantial interindividual and limited intraindividual genomic diversity among tumors from men with metastatic prostate cancer, Nat. Med, vol.22, pp.369-378, 2016. ,
Prospective genomic profiling of prostate cancer across disease states reveals germline and somatic alterations that may affect clinical decision making, JCO Precis. Oncol, 2017. ,
The long tail of oncogenic drivers in prostate cancer, Nat. Genet, vol.50, pp.645-651, 2018. ,
Genomic correlates of clinical outcome in advanced prostate cancer, Proc. Natl Acad. Sci. USA, vol.116, pp.11428-11436, 2019. ,